Clinician Reverse Pitch: What Hospitals Really Need to Use/Develop Nanomedicine, a European Perspective

Maurizio Scarpa, Regional Coordinating Center for Rare Diseases, University Hospital Udine, Italy, European Reference Network for Inherited Metabolic Diseases, MetabERN.

Abstract

The translation of nanomedicine from bench to bedside faces a critical gap between technological innovation and clinical implementation, particularly in rare and metabolic diseases where therapeutic options remain severely limited. This reverse pitch addresses the real-world needs of tertiary care centers and European Reference Networks (ERNs) in deploying nanomedicine solutions.

Hospitals require nanomedicine platforms that address three fundamental challenges: (1) blood-brain barrier penetration for neurometabolic disorders, where enzyme replacement therapies fail to reach the CNS; (2) targeted delivery systems that minimize off-target toxicity in pediatric populations, who represent the majority of metabolic disease patients; and (3) scalable manufacturing processes compatible with orphan drug economics and small patient populations.

From a clinical perspective, successful nanomedicine development must prioritize: disease-specific targeting mechanisms validated in relevant disease models; formulations that maintain long-term stability without cold chain requirements, essential for pan-European distribution; and companion diagnostics enabling patient stratification and therapeutic monitoring. The integration with existing newborn screening programs and natural history registries is crucial for early intervention strategies.

Metabolic diseases exemplify ideal conditions for nanomedicine application: well-defined molecular targets, established biomarkers, and organized patient networks through ERNs facilitating clinical trial recruitment. However, regulatory pathways for nano-enabled advanced therapy medicinal products (ATMPs) require harmonization across EU member states, while reimbursement frameworks must acknowledge the value proposition of precision nanomedicine in ultra-rare conditions.

This presentation outlines actionable priorities for academic-industrial partnerships, emphasizing that clinician-driven innovation is essential to ensure nanomedicine development addresses genuine unmet medical needs rather than pursuing technological solutions seeking clinical problems.